longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

MUX

MUX
19.0201.93%( +0.360 )

LongbridgeAI

3 Growth Companies With Up To 18% Insider Ownership

Simplywall
Sep 21, 2026 at 06:08 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

The article highlights three US growth companies with high insider ownership (16-18%): Abeona Therapeutics, Clearfield, and McEwen. It notes that significant insider stakes often align management with shareholder interests. Abeona focuses on gene therapies with strong revenue growth forecasts; Clearfield expands via distribution alliances in fiber optics; and McEwen, a gold/silver producer, recently turned profitable. The piece serves as an investment research overview based on historical data and analyst forecasts.

In the last week, the United States market has been flat, yet it has seen a 12% increase over the past year with earnings forecasted to grow by 17% annually. In this environment, growth companies with significant insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests.

Top 10 Growth Companies With High Insider Ownership In The United States

Click here to see the full list of 180 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

Abeona Therapeutics (ABEO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening diseases in the United States, with a market cap of $318.51 million.

Operations: The company's revenue segment primarily consists of its biotechnology startups, generating $25.52 million.

Insider Ownership: 16.2%

Abeona Therapeutics, known for its gene therapy ZEVASKYN, shows promising growth potential with forecasted annual revenue growth of 41.5%, surpassing the US market average. Despite recent financial losses and substantial insider selling over the past quarter, the company is expected to become profitable within three years. Recent announcements include UF Health as a new treatment center for ZEVASKYN and receiving New Technology Add-On Payment status from CMS, enhancing access to innovative therapies.

  • Take a closer look at Abeona Therapeutics' potential here in our earnings growth report.
  • The analysis detailed in our Abeona Therapeutics valuation report hints at an inflated share price compared to its estimated value.

Clearfield (CLFD)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products globally with a market cap of $409.69 million.

Operations: The company's revenue segment consists of $153.66 million from its fiber management, protection, and delivery products both domestically and internationally.

Insider Ownership: 18.5%

Clearfield is expanding its market presence through a new distribution alliance with WAV, enhancing its reach in the wireless sector. The company's revenue growth forecast of 17.5% annually outpaces the US market, although profit margins have decreased from last year. Despite being dropped from several growth benchmarks, Clearfield was added to defensive indices and continues to innovate with its fiber optic sensing solutions. Analysts predict a potential stock price increase of 33.5%.

  • Get an in-depth perspective on Clearfield's performance by reading our analyst estimates report here.
  • According our valuation report, there's an indication that Clearfield's share price might be on the expensive side.

McEwen (MUX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: McEwen Inc. is involved in the exploration, development, production, and sale of gold and silver deposits across the United States, Canada, Mexico, and Argentina with a market cap of $1.17 billion.

Operations: The company's revenue segments include the Fox Complex generating $97.74 million and the Gold Bar Mine Complex contributing $130.53 million.

Insider Ownership: 16.4%

McEwen's strong insider ownership aligns with its significant growth prospects, as earnings are forecast to grow 59.2% annually, surpassing the US market. The company recently became profitable and is trading at a favorable price-to-earnings ratio of 14.5x. Despite no recent insider trading activity, McEwen's strategic initiatives, such as the partnership with Paragon Advanced Labs for laboratory services and leadership promotions following COO William Shaver’s retirement, support its ambitious production goals.

  • Unlock comprehensive insights into our analysis of McEwen stock in this growth report.
  • Upon reviewing our latest valuation report, McEwen's share price might be too pessimistic.

Make It Happen

  • Click through to start exploring the rest of the 177 Fast Growing US Companies With High Insider Ownership now.
  • Searching for a Fresh Perspective? Trump has pledged to "unleash" American oil and gas and these 80 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Login to unlock4,692characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Abeona Therap

Abeona Therap

USABEO

-0.55%

Clearfield

Clearfield

USCLFD

+1.77%

McEwen

McEwen

USMUX

+1.93%